Cargando…
Impact of pre-enrolment medication use on clinical outcomes in SUMMIT
The impact of prior treatment on results of clinical trials in chronic obstructive pulmonary disease (COPD) has been debated. We used data from the Study to Understand Mortality and Morbidity in COPD Trial to examine the impact of prior treatment on the effects of randomised study drugs on mortality...
Autores principales: | Vestbo, Jørgen, Dransfield, Mark, Anderson, Julie A., Brook, Robert D., Calverley, Peter M.A., Celli, Bartolome R., Cowans, Nicholas J., Crim, Courtney, Martinez, Fernando, Newby, David E., Yates, Julie, Lange, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387990/ https://www.ncbi.nlm.nih.gov/pubmed/30815468 http://dx.doi.org/10.1183/23120541.00203-2018 |
Ejemplares similares
-
Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
por: Byrd, James Brian, et al.
Publicado: (2018) -
Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
por: Celli, Bartolome R, et al.
Publicado: (2019) -
Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial
por: Brigham, Emily P., et al.
Publicado: (2021) -
FEV(1) is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
por: Bikov, Andras, et al.
Publicado: (2020) -
Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease
por: Adamson, Philip D., et al.
Publicado: (2018)